The IL-15-based superagonist ALT-803 promotes the antigen-independent conversion of memory CD8 + T cells into innate-like effector cells with antitumor activity

Oncoimmunology. 2013 Nov 1;2(11):e26442. doi: 10.4161/onci.26442. Epub 2013 Oct 9.

Abstract

ALT-803, an interleukin-15-based superagonist, induces memory CD8+ T cells to proliferate, upregulate receptors involved in innate immunity, secrete interferon γ and acquire the ability to kill malignant cells in the absence of antigenic stimulation. Thus, ALT-803 can promote the expansion and activation of memory CD8+ T cells while converting them into innate immune effector cells that exhibit robust antineoplastic activity.

Keywords: NKG2D; adaptive immunity; immunotherapy; innate immunity; interferon γ; interleukin-15; memory CD8+ T cells; myeloma; tumor.

Publication types

  • Research Support, N.I.H., Extramural